Targeting multiple signal transduction cascades (NF-κB, PI3K/AKT, and AP-1) can constitute an important pharmacological strategy as deregulation of these oncogenic pathways has been reported to mediate both initiation and progression of MM [33,53]. Here, JUN is linked to Miyoshi myopathy.